ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Press release Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome December 08, 2023
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 23, 2024
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium Press release … is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called … June 28, 2022
ProQR to Participate in the Kempen Life Sciences Conference Press release … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … April 19, 2022
ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release … A presentation titled “Therapeutic RNA editing by Axiomer ® editing oligonucleotides” by Janne Turunen, PhD, … February 06, 2018
ProQR to Webcast Virtual Analyst Event on November 18 Press release … to highlight its clinical stage pipeline programs and the Axiomer ® RNA editing platform. ProQR leadership will … November 11, 2021
ProQR Announces Expert Perspectives Conference Call Series Press release … pigmentosa and ProQR’s RNA oligonucleotide platform and Axiomer RNA editing approaches. Event Details Date/Time: June … June 12, 2020
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 Press release … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … April 26, 2022
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 24, 2017
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release Key updates September 25, 2017